Nxera Pharma has acquired 1 company.
Nxera Pharma’s largest acquisition to date was in 2015, when it acquired Heptares Therapeutics for $400M. The Company’s most targeted sectors include life science (100%).
Midtown East 9-7-2 Akasaka,
Minato,
107-0052
Japan,
+81 3 5962 5718
www.nxera.life
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2015-02-22 |
Heptares Therapeutics Ltd. · Life Science
Welwyn Garden City, United Kingdom · www.heptares.com Heptares Therapeutics Ltd. is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Its proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Advisors: Covington & Burling , Goldman Sachs |
400 | Add-on Acquisition |
Nxera Pharma
|
- | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
